Literature DB >> 21950746

Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

Leon A Adams1, Jacob George, Elisabetta Bugianesi, Enrico Rossi, W Bastiaan De Boer, David van der Poorten, Helena L I Ching, Max Bulsara, Gary P Jeffrey.   

Abstract

BACKGROUND AND AIM: Significant hepatic fibrosis is prognostic of liver morbidity and mortality in non-alcoholic fatty liver disease (NAFLD); however, it remains unclear whether non-invasive fibrosis models can determine this end-point. We therefore compared the accuracy of simple bedside versus complex fibrosis models across a range of fibrosis in a multi-centre NAFLD cohort.
METHODS: Simple (APRI, BARD) and complex (Hepascore, Fibrotest, FIB4) fibrosis models were calculated in 242 NAFLD subjects undergoing liver biopsy. Significant (F2-4) and advanced fibrosis (F3,4) were defined using Kleiner criteria. Models were compared using area under the receiver operator characteristic curves (AUC). Cut-offs were determined by Youden Index or 90% predictive values.
RESULTS: For significant fibrosis, non-invasive fibrosis models had modest accuracy (AUC 0.707-0.743) with BARD being least accurate (AUC 0.609, P < 0.05 vs others). Using single cut-offs, sensitivities and predictive values were < 80%; using two cut-offs, > 75% of subjects fell within indeterminate ranges. Simple models had significantly more subjects within indeterminate ranges than complex models (99.1-100% vs 82.1-84.4% respectively, P < 0.05 for all). For advanced fibrosis, complex models were more accurate than BARD (AUC 0.802-0.858 vs 0.701, P < 0.05). Using two cut-offs, complex models had fewer individuals within indeterminate ranges than BARD (11.1-32.3% vs 70.7%, P < 0.01 for all). For cirrhosis, complex models had higher AUC values than simple models.
CONCLUSIONS: In NAFLD subjects, non-invasive models have modest accuracy for determining significant fibrosis and have predictive values less than 90% in the majority of subjects. Complex models are more accurate than simple bedside models across a range of fibrosis.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21950746     DOI: 10.1111/j.1440-1746.2011.06774.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  43 in total

1.  Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.

Authors:  Naim Alkhouri; Arthur J McCullough
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-10

2.  Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.

Authors:  J Cui; B Ang; W Haufe; C Hernandez; E C Verna; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2015-04-15       Impact factor: 8.171

Review 3.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

4.  Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.

Authors:  Hwa-Li Tan; Shamsul Mohd Zain; Rosmawati Mohamed; Sanjay Rampal; Kin-Fah Chin; Roma Choudhury Basu; Phaik-Leng Cheah; Sanjiv Mahadeva; Zahurin Mohamed
Journal:  J Gastroenterol       Date:  2013-06-26       Impact factor: 7.527

Review 5.  NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?

Authors:  Shivaram P Singh; Rakesh K Barik
Journal:  J Clin Exp Hepatol       Date:  2019-09-21

6.  Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Saumya Jayakumar; Stephen A Harrison; Rohit Loomba
Journal:  Curr Hepatol Rep       Date:  2016-04-21

Review 7.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12

Review 8.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

9.  Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Authors:  Zobair M Younossi; Rohit Loomba; Quentin M Anstee; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Zachary D Goodman; Naga P Chalasani; Kris V Kowdley; Jacob George; Keith Lindor
Journal:  Hepatology       Date:  2018-07       Impact factor: 17.425

10.  Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001-2010.

Authors:  Anqi Wang; Mariana Lazo; H Ballentine Carter; John D Groopman; William G Nelson; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-06-03       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.